Irbesartan Azevedos

Irbesartan, the active ingredient in Irbesartan Azevedos, is a angiotensin II receptor blocker presented as an oral dosage form for oral use. Approved in the European Union, it treats hypertension and diabetic nephropathy in adult patients, providing long‑term blood pressure control and renal protection.

GNH USA supplies Irbesartan Azevedos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with reliable quality assurance and adherence to EU GMP standards.

Irbesartan, an angiotensin II receptor blocker, is used to manage conditions involving the renin‑angiotensin system.

- Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Proteinuria: reduces urinary protein excretion in patients with renal disease.

Irbesartan may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat that can impair breathing. - Hyperkalemia: elevated serum potassium that may cause cardiac arrhythmias. - Acute renal impairment: sudden decline in kidney function, indicated by rising creatinine. - Hepatic injury: abnormal liver enzymes or jaundice. - Severe hypotension: markedly low blood pressure leading to dizziness or fainting.

When prescribing Irbesartan, several safety considerations should be observed.

- Blood pressure monitoring: regularly check to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium monitoring: watch for hyperkalemia, especially with potassium‑sparing agents. - Pregnancy caution: avoid use during the second and third trimesters due to potential fetal toxicity. - Drug interaction review: assess concomitant medications for additive effects on potassium or renal function. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Irbesartan can interact with several medicines; the significance varies.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use may increase renal risk. - Dual ARB/ACE‑inhibitor therapy: may cause severe hypotension and renal dysfunction. - Potassium‑sparing diuretics: additive risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function. - Lithium: increased lithium levels can lead to toxicity. - CYP3A4 inhibitors (e.g., azole antifungals): may raise irbesartan plasma concentrations.